| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm |
| Cash burn (monthly) | 2.69 mm | (no burn) | 3.78 mm | 3.66 mm | 2.70 mm | 3.08 mm |
| Cash used (since last report) | 7.50 mm | n/a | 10.54 mm | 10.20 mm | 7.53 mm | 8.59 mm |
| Cash remaining | 17.15 mm | n/a | 14.11 mm | 14.45 mm | 17.12 mm | 16.06 mm |
| Runway (months of cash) | 6.4 | n/a | 3.7 | 4.0 | 6.3 | 5.2 |
| 13F holders | Current |
|---|---|
| Total holders | 9 |
| Opened positions | 1 |
| Closed positions | 9 |
| Increased positions | 1 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 340.07 mm |
| Total shares | 17.41 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| John Howard Burbank III | 4.60 mm | $1.26 mm |
| OrbiMed Israel BioFund GP Limited Partnership | 4.55 mm | $1.25 mm |
| Centaurus Investments | 2.84 mm | $779.00 k |
| Cystic Fibrosis Foundation | 2.75 mm | $990.00 k |
| TAK Takeda Pharmaceutical Company Limited | 1.48 mm | $3.65 mm |
| 8VC GP I | 1.09 mm | $304.13 mm |
| MMCAP International Inc. SPC | 96.81 k | $26.33 mm |
| PNC The PNC Financial Services Group, Inc. | 4.00 k | $1.12 mm |
| UBS UBS | 2.00 k | $560.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Sep 24 | Solomon Jonathan Eitan | Common Stock | Grant | Acquire A | No | No | 0 | 50,556 | 0.00 | 53,056 |
| 16 Sep 24 | Oron Assaf | Common Stock | Grant | Acquire A | No | No | 0 | 25,804 | 0.00 | 25,804 |
| 16 Sep 24 | Merav Bassan | Common Stock | Grant | Acquire A | No | No | 0 | 31,749 | 0.00 | 31,749 |
| 15 Jul 24 | Flynn James E | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 5,883,000 | 0.00 | 8,938,049 |
| 15 Jul 24 | Flynn James E | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 5,883,000 | 0.00 | 8,938,049 |
| 15 Jul 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | Yes | No | 0 | 5,883 | 0.00 | 47,957 |
| 15 Jul 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | Yes | No | 0 | 5,883 | 0.00 | 47,957 |
| 11 Jul 24 | Gregory Louis Merril | Common Stock Options - Right to Buy Common Stock | Grant | Acquire A | No | No | 0.363 | 264,000 | 95.83 k | 264,000 |
